Tradition Capital Management LLC Sells 465 Shares of Becton, Dickinson and Company (BDX)

Tradition Capital Management LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 4.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,705 shares of the medical instruments supplier’s stock after selling 465 shares during the quarter. Tradition Capital Management LLC owned 4,264.62% of Becton, Dickinson and worth $1,902,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Maple Capital Management Inc. grew its position in shares of Becton, Dickinson and by 56.3% during the third quarter. Maple Capital Management Inc. now owns 1,665 shares of the medical instruments supplier’s stock worth $326,000 after buying an additional 600 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Becton, Dickinson and by 4.4% during the third quarter. Principal Financial Group Inc. now owns 949,651 shares of the medical instruments supplier’s stock worth $186,084,000 after buying an additional 40,416 shares in the last quarter. Oregon Public Employees Retirement Fund grew its position in shares of Becton, Dickinson and by 9.6% during the third quarter. Oregon Public Employees Retirement Fund now owns 24,278 shares of the medical instruments supplier’s stock worth $4,757,000 after buying an additional 2,130 shares in the last quarter. Daiwa Securities Group Inc. grew its position in shares of Becton, Dickinson and by 42.5% during the third quarter. Daiwa Securities Group Inc. now owns 9,137 shares of the medical instruments supplier’s stock worth $1,790,000 after buying an additional 2,727 shares in the last quarter. Finally, United Asset Strategies Inc. acquired a new stake in shares of Becton, Dickinson and during the third quarter worth approximately $338,000. 86.01% of the stock is owned by institutional investors.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stephen Sichak sold 11,787 shares of the firm’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the completion of the sale, the insider now owns 14,038 shares in the company, valued at $2,814,057.48. The disclosure for this sale can be found here. Insiders sold 53,187 shares of company stock worth $10,720,847 over the last quarter. 1.40% of the stock is currently owned by company insiders.

WARNING: “Tradition Capital Management LLC Sells 465 Shares of Becton, Dickinson and Company (BDX)” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/11/13/tradition-capital-management-llc-sells-465-shares-of-becton-dickinson-and-company-bdx.html.

A number of research firms have recently weighed in on BDX. Stifel Nicolaus reissued a “buy” rating and set a $245.00 price target on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Morgan Stanley raised their price target on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Royal Bank Of Canada reissued a “sector perform” rating and set a $230.00 price target (up previously from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target for the company in a research report on Tuesday, October 31st. Finally, Wells Fargo & Company reissued a “positive” rating and set a $235.00 price target (up previously from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $213.47.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at $218.04 on Monday. The company has a quick ratio of 5.01, a current ratio of 5.56 and a debt-to-equity ratio of 1.48. The stock has a market capitalization of $49,889.07, a price-to-earnings ratio of 23.10, a price-to-earnings-growth ratio of 1.72 and a beta of 1.04. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $225.23.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. The company had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same period last year, the business posted $2.12 earnings per share. equities research analysts anticipate that Becton, Dickinson and Company will post 10.63 EPS for the current fiscal year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply